Results 151 to 160 of about 60,195 (236)
ABSTRACT Introduction Brachytherapy is a widely accepted treatment for prostate cancer, in which subsequent radiation‐associated enteric‐type urethral adenocarcinoma is extremely rare. Case Presentation An 83‐year‐old man with a history of cholecystitis, appendicitis, and hyperlipidemia who had undergone brachytherapy 20 years earlier presented with ...
Yuki Tanaka +6 more
wiley +1 more source
Management and Treatment Strategies for Upper Tract Urothelial Carcinoma: Current Insights. [PDF]
Dadabhoy AS +3 more
europepmc +1 more source
Rectal mucinous adenocarcinoma mimicking prostatic urothelial carcinoma: A diagnostic and therapeutic challenge. [PDF]
Homeniuk A, Ge R.
europepmc +1 more source
ABSTRACT Introduction Enfortumab vedotin is a Nectin‐4‐directed antibody–drug conjugate approved for metastatic urothelial carcinoma. Cardiac adverse events such as pericardial effusion or tamponade associated with enfortumab vedotin are extremely rare. Case Presentation A 50‐year‐old man with metastatic UC developed chest pain and dyspnea 3 days after
Hiroto Akamatsu +7 more
wiley +1 more source
Clinical Trials and Emerging Therapeutic Paradigms in Upper-Tract Urothelial Carcinoma. [PDF]
Chavarriaga J, Raman JD.
europepmc +1 more source
ABSTRACT Introduction Although prostate‐specific antigen (PSA) screening has facilitated early detection of prostate cancer, approximately 5% of patients still present with distant metastases at diagnosis. Ureteral metastasis from prostate cancer is extremely rare.
Hiroshi Ushida +3 more
wiley +1 more source
Urothelial Carcinoma of the Bladder with a Single Pancreatic Metastasis: A Case Report. [PDF]
Calabrese B +4 more
europepmc +1 more source
Long‐term outcomes following a 5‐year recurrence‐free interval in non‐muscle‐invasive bladder cancer
Objective To describe the recurrence and progression trends of non‐muscle‐invasive bladder cancer (NMIBC) during a 14‐year period in Denmark between 2009 and 2022. Furthermore, to evaluate the risk of late recurrence with or without progression in patients who initially experience a 5‐year recurrence‐free interval (RFI).
Peter B. Hjort +2 more
wiley +1 more source
Bacillus Calmette-Guérin therapy in the management of upper tract urothelial carcinoma in-situ: a systematic review. [PDF]
Garras Y +3 more
europepmc +1 more source
A Delphi consensus for implementing genomic testing in unresectable or metastatic urothelial cancer
Objectives To establish a UK consensus vision of a standardised genomic testing pathway in unresectable/metastatic urothelial cancer (mUC) with clear roles and responsibilities for multidisciplinary team (MDT) members and molecular pathology laboratory teams, and to agree how the pathway must evolve to accommodate emerging innovations.
Syed A. Hussain +7 more
wiley +1 more source

